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bstract
Prevalence of pituitary incidentaloma is variable: between 1.4% and 27% at autopsy, and between 3.7% and 37% on imaging. Pituitary
icroincidentalomas (serendipitously discovered adenoma < 1 cm in diameter) may increase in size, but only 5% exceed 10 mm. Pituitary macroin-
identalomas (serendipitously discovered adenoma > 1 cm in diameter) show increased size in 20–24% and 34–40% of cases at respectively 4 and
 years’ follow-up. Radiologic differential diagnosis requires MRI centered on the pituitary gland. Initial assessment of nonfunctioning (NF)
icroincidentaloma is firstly clinical, the endocrinologist looking for signs of hypersecretion (signs of hyperprolactinemia, acromegaly or Cush-
ng’s syndrome), followed up by systematic prolactin and IGF-1 assay. Initial assessment of NF macroincidentaloma is clinical, the endocrinologist
ooking for signs of hormonal hypersecretion or hypopituitarism, followed up by hormonal assay to screen for hypersecretion or hormonal deficiency
nd by ophthalmologic assessment (visual acuity and visual field) if and only if the lesion is near the optic chiasm (OC). NF microincidentaloma
f less than 5 mm requires no surveillance; those of ≥  5 mm are not operated on but rather monitored on MRI at 6 months and then 2 years.
acroincidentaloma remote from the OC is monitored on MRI at 1 year, with hormonal exploration (for anterior pituitary deficiency), then every years. When macroincidentaloma located near the OC is managed by surveillance rather than surgery, MRI is recommended at 6 months, with
ormonal and visual exploration, then annual MRI and hormonal and visual assessment every 6 months. Surgery is indicated in the following cases:
volutive NF microincidentaloma, NF macroincidentaloma associated with hypopituitarism or showing progression, incidentaloma compressing
he OC, possible malignancy, non-compliant patient, pregnancy desired in the short-term, or context at risk of apoplexy.
 2015 Elsevier Masson SAS. All rights reserved.
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ésumé
La prévalence des incidentalomes hypophysaires est variable : 1,4 à 27 % à l’autopsie; 3,7 à 37 % en imagerie. Les microincidentalomes hypophy-
aires (adénomes de découverte fortuite de moins d’un centimètre de diamètre) peuvent augmenter de taille, mais moins de 5 % d’entre eux dépassent
0 mm. Les macroincidentalomes hypophysaires (adénomes de découverte fortuite de plus d’un centimètre de diamètre) augmentent de taille dans
0–24 % ou 34–40 % des cas si la durée de suivi est respectivement de 4 ans ou 8 ans. Le diagnostic différentiel radiologique nécessite une IRM
entrée sur l’hypophyse. L’évaluation initiale d’un microincidentalome non fonctionnel (NF) est d’abord clinique, à la recherche, par un endocrino-
ogue, de signes d’hypersecrétion (signes d’hyperprolactinémie, d’acromégalie ou syndrome de Cushing), complété par un dosage systématique de
rolactine et d’IGF-1. L’évaluation initiale d’un macroincidentalome NF est clinique, à la recherche, par un endocrinologue, d’une hypersécrétion
ormonale ou d’une insuffisance antéhypophysaire (IAH), complétée par des dosages hormonaux à la recherche d’une hypersécrétion ou d’un
éficit hormonal et par une évaluation ophtalmologique (acuité visuelle et champ visuel) si et seulement si la lésion est à proximité ou au contact
u chiasma optique (CO). Les microincidentalomes NF de moins de 5 mm ne relèvent d’aucune surveillance. Les microincidentalomes NF de
iamètre ≥  5 mm ne sont pas opérés mais surveillés au moyen d’une IRM réalisée à 6 mois puis à 2 ans. Les macroincidentalomes situés à distance
u chiasma sont surveillés par une IRM à 1 an et une exploration hormonale (recherchant une IAH), puis tous les 2 ans. Pour les macroinciden-
alomes situés à proximité du chiasma, s’il est décidé de les surveiller et de ne pas les opérer, une IRM est recommandée à 6 mois avec explorations
ormonale et visuelle, puis tous les ans pour l’IRM et le bilan hormonal, et tous les 6 mois pour l’évaluation visuelle. Le traitement chirurgical est
ecommandé dans les situations suivantes : microincidentalomes NF évolutifs, macroincidentalomes NF avec IAH, ou évolutif, lésion comprimant
e chiasma optique, doute sur une lésion maligne, patient non observant, grossesse souhaitée à court terme, contexte favorisant une apoplexie.
 2015 Elsevier Masson SAS. Tous droits réservés.
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Pituitary incidentaloma is a pituitary lesion serendipitously
iscovered on brain imaging (CT, MRI or PET) performed for
ome other reason. The present consensus conference on non-
unctioning (NF) pituitary adenoma does not seek to address
he entire issue of pituitary incidentaloma, but focuses on diag-
osis and treatment of clinical nonfunctioning serendipitously
iscovered adenoma.
.  Epidemiology
The epidemiology of pituitary incidentaloma is founded on a
ew mainly retrospective studies. Frequency, assimilated to that
f NF pituitary adenoma, is thus unclear. However, the preva-
ence of clinically significant lesions was around 80 per million
ases in two studies, one British [1] and the other Belgian [2],
f adult European populations. How many of these lesions will
how clinical impact is unknown. There are no data for children.
A meta-analysis of 10 retrospective studies including slightly
ore than 3500 patients reported prevalence of 16.7% for pitu-
tary adenoma and of 0.2% for macroadenoma [3].
.1.  Prevalence  of  pituitary  incidentaloma
Prevalence of pituitary incidentaloma varies depending on
he type of examination: 1.4–27% on autopsy and 3.7–37% on
maging [3].
.1.1.  Autopsy  series
Prevalence of pituitary incidentaloma on autopsy probably
epends on the number and thickness of cross-sections.
In a Japanese series [4], the mean prevalence of pituitary
denoma was 10%, 80% being < 3 mm; macroadenoma was
xtremely rare. Differential diagnoses comprised Rathke’s cleft
yst and craniopharyngioma.
f
t
oénome
In a recent Iranian study of 485 autopsies, pituitary adenoma
as found in 12.6% of subjects, with a mean age of 43 years.
revalence was unaffected by gender, age or body-mass index
BMI) for both macro- and microadenomas [5]. Other studies,
owever, reported an age effect, with higher prevalence in elderly
ubjects [6,7]. The absence of any gender or BMI effect agrees
ith the rest of the literature, despite the greater frequency of
adiologically identified incidentaloma in females [8–11].
.1.2. Radiological  series
The frequency of incidentaloma discovered on imaging is
ncreasing with progress in techniques: CT, 1.5 or 3-Tesla MRI,
nd PET. The indication for examination also contributes greatly
o variation in prevalence. Macroadenoma may cause neurologic
ymptoms that are not initially seen as implicating adenoma.
.1.2.1. Overall  prevalence.  The percentage of serendipitously
iscovered pituitary masses in a series of 353 consecutive
atients seen in a single center over a 14-year period was 12%
12].
.1.2.2.  Prevalence  of  microincidentaloma.  On MRI, focal
ow-density areas compatible with asymptomatic pituitary
icroadenoma are found in 10% of healthy subjects [13]. On CT,
he percentage varies from 4% to 20% for hyposignal exceeding
 mm [14–18].
.1.2.3. Prevalence  of  macroincidentaloma.  On imaging, the
revalence of macroadenoma in healthy populations ranged
rom 0.11% to 0.3% [16–18] and was 0.2% on CT in an observa-
ional study in Ohio [19]. There have been isolated case reports
f pituitary incidentaloma discovered on PET scan [20].
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.2.  Imaging  indications
In a retrospective study of 46 cases diagnosed between 1993
nd 2000 [8], patient age ranged between 16 and 77 years, and
3% showed macrotumor. Indications were chronic headache
28%), cranial trauma (15.3%), sinusitis (13%) and stroke
13%). Anterior pituitary deficiency was found in 41.3% of
atients, mainly in the form of hypogonadism (30%). Surgery
as performed in 37% of cases.
In our own experience, a non-negligible number of microade-
omas are discovered on CT following falls, sometimes related
o low blood pressure and/or hyponatremia secondary to over-
ooked hypopituitarism in more elderly patients.
The question of the relationship between headache and pitu-
tary incidentaloma remains open.
.3.  Prevalence  according  to  histologic  type
.3.1.  Major  prevalences
.3.1.1.  Clinical  series.  In the clinical series reported by
ainstein Day et al., 30% of surgically managed lesions
ere gonadotroph adenomas, 40% nonsecreting multi-hormone
denomas, and 30% NF adenomas (i.e., without immunohisto-
hemical reaction to pituitary hormones) [8].
.3.1.2. Autopsy  series.  In autopsy series [4,21,22], most ade-
omas are prolactinomas, although histologically different from
rolactinomas in surgical specimens [4]. Various other types
gonadotroph, somatotroph, multi-secreting or nonsecreting
denoma) were also, but less frequently, reported.
.3.2. Silent  corticotroph  adenoma
The prevalence of silent corticotroph adenoma in 200 type-
 diabetes patients [23] was 2%. Improved prognosis under
reatment for Cushing’s syndrome, in terms of hypertension,
besity and carbohydrate intolerance, has so far been found
nly in clinical case reports. It is to be stressed that corticotroph
icroadenoma is often difficult to detect on imaging and raises
ssues of differential diagnosis with respect to nonsecreting inci-
entaloma.
.3.3. Other  diagnostic  pitfalls
.3.3.1.  Thyrotropin-secreting  adenoma.  The literature high-
ights the difficulty of distinguishing between thyrotropin-
ecreting microadenoma and selective pituitary resistance to
hyroid hormones associated to a pituitary incidentaloma
24,25]..3.3.2.  Iatrogenic  hyperprolactinemia  and  incidentaloma.
atrogenic hyperprolactinemia is another diagnostic pitfall: not
o much that induced by psychotropic drugs and anti-emetics,
hich is well known, as that induced by verapamil (Isoptine®),
hich, when associated with a pituitary incidentaloma, may give
ise to mistaken suspicion of prolactinoma [26].
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.3.3.3.  Gonadotroph  adenoma.  Gonadotroph adenoma can be
ard to distinguish from compensated peripheral gonadal insuf-
ciency associated with incidentaloma.
.  Natural  history  of  micro-  and  macroincidentaloma
To describe the natural history of NF adenoma, we need to
ook at series of patients managed without surgery by isolated
orphologic surveillance. Such studies, however, rarely have
ong-term follow-up and tend to include small series. Data are
parse, especially for NF microadenoma, although this is the
ost common form of incidentaloma.
.1.  Nonfunctioning  microadenoma
Nonfunctioning microadenoma is the most common form of
ncidentaloma; depending on the series, 50–90% of incidentalo-
as are solid tumors, 95% of which are adenomas [17,27]. More
han 99% of serendipitously discovered adenomas are microade-
omas [3,13,16,18,28]. These percentages agree with autopsy
ata, with 0.3% microadenomas [29], suggesting that progres-
ion from micro- to macroadenoma is very rare. The frequency of
icroadenoma growth was estimated at 3.3% of patients per year
30]. Increased size was reported in 10 out of 74 microadenoma
atients (13%) [27], only 3 of whom had developed macroade-
oma by 6–8 years after diagnosis, size increasing in the others
y 1–2 mm over periods ranging from 18 months to 10 years;
 of the 74 actually showed reduction in size. Another study
eported 12.5% increase in microadenoma size at 2 years, in 2
ut of 16 patients [31]. Molitch reported size increase in 10% of
icroadenomas and decrease in 6%, at follow-up ranging from
.5 to 8 years (n  = 160) [29].
Finally, microadenoma growth is possible but rare (10–13%
f cases) and fewer than 5% of lesions grow to more than 1 cm
ver long-term follow-up, and even so without becoming life-
hreatening. Increase in size may be found as of 18 months’
ollow-up but is minimal (1–2 mm); growth to the macroade-
oma stage has been reported only with at least 6 years’
ollow-up.
.2.  Nonfunctioning  macroadenoma
Nonfunctioning macroadenoma accounts for about 1% of
ncidentalomas [3]. Macroadenoma has a greater tendency to
row than microadenoma (12.5% of patients per year vs. 3.3%).
olid lesions show greater progression than cystic lesions (5.7%
f patients per year vs. 0.05%) [27,30]. In a series of 115 NF inci-
entalomas, growth was reported in 20% of cases at 4 years [27].
n a review of 353 macroincidentalomas [29], size increase was
ound in 24% of cases and decrease in 12%; the rate of increase
aried with follow-up: 17% for follow-up < 4 years (38/215) and
4% for follow-up 5–8 years (47/138).
Macroadenoma in contact with the optic chiasm requires mor-
hologic and ophthalmologic surveillance, so as to be able to
ecommend surgery in case of onset of visual disorder [32,33].
 study of 24 microadenomas, 5 of which were inducing visual
isorder at inclusion, found size increase in 50% of cases and
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pituitary lobe, slightly deforming the sellar diaphragm, eroding
the adjacent floor and pushing back the stalk. Signal may be94 F. Galland et al. / Annales d’E
orsening or onset of visual disorder in 67% [33]. Surgical
anagement of NF incidentaloma shows better prognosis than
n symptomatic adenoma in terms of 5-year recurrence [34]. The
isk of apoplexy is minimal (1%, and 10% at 5 years) but higher
n macroadenoma adjacent to the optic chiasm in patients under
nticoagulation therapy [17,30,35].
Finally, progression of NF adenoma is associated with the
evelopment of anterior pituitary deficiency in 2.4 per 100
atients per year [30]. Certain studies reported improved pitu-
tary function following surgery [36] whereas others did not
ention any change or else reported deterioration.
In all, increasing macroadenoma size is reported in 20% of
ases at 4 years and in 40% at 8 years. Solid tumors show greater
rogression than cystic lesions. Surveillance is therefore manda-
ory in view of the risk of visual impairment and anterior pituitary
eficiency.
.  Radiologic  differential  diagnoses
As seen above, serendipitous discovery of pituitary abnor-
ality on imaging is frequent, with a rate of up to 20% on CT
nd 38% on MRI [37].
The main diagnostic factors on imaging are based on sella
urcica size, exact lesion topology, degree of tumoral uptake,
alcification and intralesional fluid level.
This requires repeat MRI centered on the sella turcica, with
 rigorous protocol (cf. Raverot et al. in this issue), if the initial
xamination was for other purposes.
In case of a “solid” mass in the sellar region, the rationales
or the various differential diagnoses are the following:
 macroadenomas are centered in the sella turcica, which is
enlarged; contrast medium uptake is not intense; there may be
small areas of necrotic-hemorrhagic remodeling with variable
signal on T1 and T2-weighted sequences; in case of extension
into the cavernous sinus, the diameter of the internal carotid
artery is respected;
 meningioma of the sellar tubercle does not enlarge the sella
turcica. A normal pituitary gland is generally visible under
the tumor. Tumor uptake is intense, frequently with a line
of enhancement of the dura mater (so-called “comet tail” or
“dural tail”), with 75% sensitivity and 94% specificity [38];
 meningioma of the cavernous sinus with extension to but
not enlargement of the sella turcica is centered on the cav-
ernous sinus, shows intense enhancement and compresses the
internal carotid artery;
 hypophysitis should be systematically considered in women
in the peripartum period in case of a mass within and above
the sella turcica without enlarging it, showing a regular and
harmonious aspect, with intense uptake if injection is possi-
ble;
 chordoma may mimic invasive macroadenoma with inferior
extension. It is more centered on the clivus than is adenoma,
and more precisely on the notochordal remnant, which shows
lysis. Extension may be toward the sphenoid sinus then the
sella turcica, with lysis of the sellar floor. A normal pitu-
itary gland is usually visible above the tumor. Signal on
v
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T2-weighted sequences is often heterogeneous, with variable
uptake. There may be intratumoral calcifications;
 depending on the clinical context, consideration should also
obviously be given to metastasis to the sellar region (generally,
extension to the posterior pituitary lobe, from breast or lung
cancer, etc.), or a granulomatosis or lymphoma.
.1.  Cystic  mass  in  the  sellar  region
In case of cystic mass in the sellar region, the arguments for
ecrotic adenoma or other differential diagnoses are as follows:
 necrotic macroadenoma is centered on the sella turcica, which
is enlarged. A fluid level (best seen on sagittal T2-weighted
slice) may be found. The tumor wall shows clear contrast
uptake;
 cystic craniopharyngioma may show an aspect similar to that
of necrotic adenoma but the sella turcica is often of normal
size; intratumoral calcification and absence of fluid level in
the cystic part suggest cystic craniopharyngioma;
 strictly medial Rathke’s cleft cyst between the anterior and
posterior pituitary lobes shows variable signal on T1 and
T2-weighted sequences, without uptake, calcification or fluid
level;
 arachnoid cyst of the sellar region is easily differentiated from
necrotic macroadenoma: although it may enlarge the sella
turcica, signal on T1 and T2 is systematically identical to that
of the CSF, and the walls show no uptake.
.2.  “Large”  pituitary  gland
In case of “large” pituitary gland, holosellar adenoma needs
o be differentiated from:
 physiological hypertrophy (pregnancy, adolescence);
 pituitary involvement in inflammatory disease, and
hypophysitis, usually with a particular clinical context;
 intracranial hypotension syndrome suggested by orthostatic
headache associated with other MRI signs of intracranial
hypotension, notably hypertrophic pachymeningitis;
 any intrasellar tumor other than adenoma (meningioma,
metastasis, etc.), although these are much less frequent. Clin-
ical context (primary cancer, diabetes insipidus [39], etc.) and
intense contrast medium uptake generally allow diagnosis.
.3.  Intrasellar  “microlesion”
In case of intrasellar “microlesion”, microadenoma is sug-
ested by: small mass < 10 mm, often lateralized in the anteriorariable: classically, low signal on T1 and high signal on T2 in
H-secreting microadenoma. Uptake after injection is minimal.
ifferential diagnosis with respect to Rathke’s cleft microcyst
nd small intrasellar craniopharyngioma is difficult.
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.  Essential  assessment  in  pituitary  incidentaloma
.1.  Clinical  assessment
We recommend primary assessment in endocrinology. Apart
rom the clinical assessment, this allows the pathology to be
xplained to the patient, relieving some of the anxiety caused by
he discovery of disease when there were no symptoms.
The interview focuses first on history, and particularly famil-
al and personal endocrine history; multiple endocrine pathology
s rare, but should be looked for in young patients: type-1 mul-
iple endocrine neoplasia, Carney complex, McCune-Albright
yndrome, familial isolated pituitary adenoma, etc.
We then turn to the symptoms that led to serendipitous discov-
ry of probable pituitary adenoma. A possible link with headache
which motivated imaging examination) and pituitary adenoma
s to be discussed.
Interview and clinical examination explore possible hyper-
ecretion of prolactin (classically, amenorrhea-galactorrhea
yndrome in women, impaired libido, gynecomastia in men),
H (signs of acromegaly) or ACTH (clinical or infraclinical
ushing’s syndrome).
In case of lesions suggesting macroadenoma, signs of
ypopituitarism and/or tumoral syndrome (headache, chiasm
yndrome) should be looked for.
In large lesions close to the optic chiasm, chiasm syndrome
hould be looked for, firstly by clinical finger analysis of the
isual field to screen for bitemporal hemianopsia; results are to
e confirmed by visual field examination by an orthopist.
The 2011 Endocrine Society guidelines [37] are in agreement
ith the above.
.2.  Essential  biological  assessment
The Endocrine Society guidelines [37] recommend system-
tic full clinical and biological assessment in all cases of pituitary
ncidentaloma. The biological assessment comprises: explo-
ation for systematic prolactin and GH hypersecretion and, in
ase of Cushing’s syndrome, exploration for cortisol and ACTH
ypersecretion; and exploration for hypopituitarism, with assays
f all anterior pituitary hormones and the corresponding periph-
ral hormones.
The present French consensus document focuses on serendip-
tously discovered adenoma, with a distinction drawn between
icroadenoma (or microincidentaloma) and macroadenoma (or
acroincidentaloma), unlike in the 2011 Endocrine Society
uidelines [37]. This distinction appeared appropriate, and we
hall present the rationale, always bearing in mind an important
spect: that of cost.
.2.1.  Serendipitously  discovered  microadenoma
.2.1.1.  Is  it  recommended  to  explore  for  prolactin,  GH  or
CTH hypersecretion?.  The factors to be considered here arehe following: increasing incidence of discovery of such lesions,
ue to increasing use of imaging; respective frequencies of the
arious histologic types of microincidentaloma found in surgi-
al and autopsy series (NF/gonadotroph adenoma is much more
•
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requent than prolactinoma, which in turn is more frequent than
omatotroph adenoma, which in turn is more frequent than cor-
icotroph adenoma; cf. Epidemiology section above); hormone
ssay costs; and the lack of evidence in the literature (small
eterogeneous series).
4.2.1.1.1.  Should  prolactin  assay  be  systematic?.  The
iterature, although still insufficient, now provides enough jus-
ification for prescribing prolactin assay. The series are small
nd heterogeneous but, epidemiologically, prolactin-secreting
icroincidentalomas are fairly frequently reported: 5 out of
2 microincidentalomas, all in female subjects, in Feldkamp
t al.’s series [40], and 7 out of 46 incidentalomas (not distin-
uishing micro- and macroincidentaloma), all in male subjects,
n Fainstein Day et al.’s series [8]. Some older series, on the
ther hand, find none [41,42]. Finally, in a large autopsy series,
32 out of 334 adenomas (39.5%, all microadenomas of 0.1
o 6 mm diameter, median 1.2 mm) were prolactin-positive on
mmunolabeling [43].
4.2.1.1.2.  Particular  situations  in  prolactin  assay.  Mod-
rately elevated prolactinemia suggests macroprolactinemia
aggregates of prolactin molecules without any clinical con-
equence). By definition, this prolactin assay artifact is not
ssociated with any symptoms of hyperprolactinemia (cf.
averot et al.).
Guideline:
•  systematic  prolactin  assay  is  recommended
in case  of  microincidentaloma  suggesting
microadenoma.
4.2.1.1.3.  Should  IGF-1  assay  be  systematic?.  According
o the currently available epidemiological data, somatotroph
denoma is rare and mainly comprises macroadenoma. One of
he main reasons for this is late diagnosis of GH hypersecretion,
s clinical signs develop very slowly and are long overlooked.
he considerations to be taken into account in recommending
ystematic IGF-1 assay or not are the following:
 do somatotroph microadenomas immediately secrete enough
GH to elevate IGF-1 levels; what is the threshold tumor vol-
ume beyond which IGF-1 is elevated in case of GH-secreting
adenoma? What is the natural history of GH-secreting ade-
noma? Unfortunately, there are at present no clear answers to
these questions;
 are GH-secreting microincidentalomas frequent enough for
systematic IGF-1 assay to be recommended? Here again, the
literature is limited, as series were small. Silent somatotroph
adenoma is rare. A series of 3048 autopsies reported 334 ade-
nomas, including 1.8% positive for GH on immunolabeling
[43]; the cost of systematic assay is to be borne in mind;
 the Endocrine Society guidelines [37] suggest systematic
IGF-1 assay for all pituitary incidentalomas. The rationale
is based on the above epidemiological considerations and on
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the fact that treatment of somatotroph adenoma is surgical
and GH-secreting microadenoma could be cured by surgery.
Guideline:
• systematic  IGF-1  assay  is  recommended  in  hor-
monal  assessment  of  microincidentaloma.
4.2.1.1.4.  Should  there  be  systematic  exploration  for  cor-
isol hypersecretion?.  Here again, the argument is based on
pidemiology. Secreting corticotroph adenoma (implicated in
linical Cushing’s syndrome) is rare, and mainly in the form of
icroadenoma. In a series of 3048 autopsies, 13.8% of the 334
ituitary adenomas expressed ACTH [43]. At present, there are
o reported cases of infraclinical Cushing’s syndrome associated
ith pituitary microadenoma.
Guideline:
• it  would  not  seem  useful  to  explore  for  cortisol
hypersecretion  in  pituitary  microincidentaloma
(asymptomatic  by  deﬁnition).
Certain teams prescribe ACTH assay [44]. But ACTH may be
levated without biological evidence of cortisol hypersecretion,
indering indications.
Guideline:
• exploration  for  cortisol  hypersecretion  and/or
ACTH assay  are  not  recommended  system-
atically but  only  in  case  of  clinical  signs  of
Cushing’s syndrome.  (This  chapter  does  not
deal with  biological  diagnosis  of  Cushing’s  syn-
drome.).
The above is in agreement with Endocrine Society guidelines
37].
4.2.1.1.5.  Is  systematic  dynamic  testing  recommended
o explore  for  hormonal  hypersecretion?.  The interest of
ynamic testing to explore for hormonal hypersecretion (other
han hypercorticism) is highly controversial (cf. Raverot et al.).
Guideline:
• systematic  dynamic  testing  is  not  recom-
mended.
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.2.1.2.  Should  anterior  pituitary  insufﬁciency  be  explored  for
n case  of  pituitary  microincidentaloma?.  There is only one
ublication on this subject [45]. Fifty percent of the 38 patients
ith NF pituitary microadenoma showed anterior pituitary
nsufficiency, defined by at least one deficit. The most frequent
eficit was for GH, shown on dynamic testing (GHRH-Arginine)
ith normal IGF-1 levels. The second was thyrotropin deficit.
his study is alone in going against the classic concept accord-
ng to which only macroadenoma can induce anterior pituitary
nsufficiency.
There have been no prospective studies comparing anterior
ituitary insufficiency according to microincidentaloma size.
The Endocrine Society guidelines for pituitary incidentaloma
37] took account of the above-mentioned publication, recom-
ending exploration for anterior pituitary insufficiency in case
f large microincidentaloma (e.g., 6–9 mm).
Guideline: systematic exploration for anterior pituitary
nsufficiency in case of pituitary microincidentaloma is not rec-
mmended. Exploration for anterior pituitary insufficiency, and
or somatotropic insufficiency in particular, may be consid-
red in 6–9 mm pituitary microincidentaloma if GH replacement
herapy is likely to be prescribed. Diagnosis requires dynamic
esting.
.2.2. Macroincidentaloma
Initial assessment of pituitary macroincidentaloma should be
erformed as for NF adenoma with clinical consequences. This
ill not be dealt with here, and is discussed in Raverot et al.
.3.  Assessment  of  visual  impairment
Guideline:
•  visual  assessment  is  not  useful  in  suspected
microadenoma;
• nor  is  it  recommended  if  the  lesion  is  remote
from the  optic  chiasm;
•  it  is,  however,  recommended  if  the  lesion  is
close to  the  optic  chiasm  or  is  seen  to  be  com-
pressing it  on  MRI.
Examination is performed by an ophthalmologist, following
he procedure recommended in the present consensus document
cf. Abouaf et al.). The diagnosis of chiasmal syndrome is critical
o treatment strategy, and especially for indications for surgery
see below).
The Endocrine Society guidelines [37] are in agreement with
his.
.4.  Role  of  biopsy  in  case  of  difﬁcult  radiologic
nterpretation
If radiologic diagnosis shows likely pituitary adenoma, there
s no reason to perform biopsy.
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Indications for biopsy in pituitary lesions are not well docu-
ented in the literature.
In lesions that are difficult to characterize radiologically
nd/or impossible to remove, biopsy may be considered, to guide
reatment.
.5.  Medical  economic  aspect
Health economics is certainly to be taken into account in
anaging pituitary incidentaloma, given its frequency. There
re, however, no updated publications comparing options from
he medical economic point of view. A single paper, from 1997,
tudied cost/benefit and quality of life impact for 4 types of
icroincidentaloma management:
 clinical surveillance;
 isolated prolactin assay, repeated only in case of elevation;
 various hormone assays, including prolactinemia, IGF-1, cor-
tisolemia after minute suppression with 1 mg dexamethasone;
 MRI surveillance at 6 and 12 months [46].
It was concluded that the second (isolated prolactin assay)
howed the best cost/benefit ratio.
.  What  type  of  management?
.1.  Surveillance?
If surgery is not initially indicated, morphologic, hormonal
nd ophthalmologic surveillance should be adapted to clini-
al presentation: initial adenoma size, proximity to the optic
hiasm, hormonal deficits, and patient age. The rationale of
urveillance concerns the risk of progression, especially in
acroadenoma, with possible onset of visual or hormonal
ffects.
As seen above, size increase, even in macroadenoma, is not
ystematic. On average, 89% of microadenomas and 75% of
acroadenomas remain stable over 2–8 years’ follow-up. Other
han in situations in which surgery is the first-line option in
atients free of comorbidity (proximity to or compression of the
hiasm), surveillance is the logical attitude.
.1.1.  Surveillance  of  NF  microincidentaloma
It is to be borne in mind that NF microincidentaloma is
ery frequent (found in 10–15% of MRIs). The present guide-
ines seek to minimize the extra cost of inappropriate close
urveillance and to reduce the anxiety of the patient (and of
he physician!).
Guidelines:
• in  NF  microadenoma  of  ≤  5  mm  diameter,  nei-
ther radiologic  nor  hormonal  surveillance  are
recommended:  it  is  more  important  to  reassure
the patient;rinologie 76 (2015) 191–200 197
•  in  NF  microadenoma  of  > 5  mm  diameter,  sim-
ple morphologic  surveillance  in  6-month  MRI
is recommended,  without  visual  or hormonal
exploration.  If  there  is  no  progression,  MRI
may be  repeated  at  2  years,  without  visual  or
hormonal exploration,  and,  if  there  is  no  pro-
gression, morphologic  surveillance  can  then  be
stopped;
• in  case  of  progression  (bearing  in  mind  that
microadenoma  rarely  evolves  into  macroade-
noma), MRI  surveillance  may  be  closer  (e.g.,
annual), to  guide  treatment  or  continued
surveillance
.1.2.  NF  macroincidentaloma
Macroadenoma increases in size more often than microade-
oma, which, given its initial size, may cause visual disorder.
his requires closer surveillance than for microincidentaloma.
The American consensus [37] recommends MRI at 6 months
hen annually for 3 years, then less frequently (whether the lesion
s close to the optic chiasm or not).
Guidelines  for  NF  macroincidentaloma
remote from  the  optic  chiasm  (suggested
criterion:  5 mm):
• MRI  at  1  year,  if  no  clinical  progression,  with
hormone exploration  for  anterior  pituitary
insufﬁciency.  Visual  exploration  (visual  ﬁeld
and acuity)  in  case  of  adenoma  in  contact  with
the chiasm  on  surveillance;
•  for  macroadenoma  remote  from  the  chiasm,
with no  tumoral  progression  at  1 year,  MRI
surveillance can  be  2-yearly,  if  no  clinical  pro-
gression. Hormone  exploration  for  anterior
pituitary insufﬁciency  can  be  annual.  Visual
exploration (visual  ﬁeld  and  acuity)  in  case  of
adenoma in  contact  with  the  chiasm  on  surveil-
lance. Visual  assessment  is  described  in Abouaf
et al.
Guidelines  for  NF  macroincidentaloma  close
to or  in  contact  with  the  optic  chiasm:
• if  surgery  is  not  indicated,  MRI  should  be
performed at  6 months,  with  hormone  explo-
ration for  anterior  pituitary  insufﬁciency  and
visual exploration  (visual  ﬁeld  and  acuity).  MRI
surveillance should  thereafter  be  annual,  with
hormone exploration.  Visual  exploration  can  be
6-monthly;
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•  in  case  of  visual  impact,  tumor  progression
or anterior  pituitary  insufﬁciency,  surgery  may
be proposed  (seeing  following  subsection).  If
surveillance is  continued  (comorbidity,  etc.),  it
should  continue  as  above.
.2.  What  indication(s)  for  surgery?
Incidentaloma should be managed by a reference multidisci-
linary team experienced in pituitary surgery, as complication
ates correlate with experience [47].
The technique (preferably endonasal endoscopic) and
pproach (transsphenoid except in case of posterior and lateral
ntracranial extension toward the Sylvian fissure) do not vary
hether discovery is serendipitous or not, but only according to
umoral anatomy.
In absence of symptoms, informed discussion with the patient
s especially important.
In NF incidentaloma, indications for surgery depend:
 on tumor anatomy (large volume; cystic aspect or not; cav-
ernous sinus invasion);
 on clinical criteria (age, physiological status, comorbidity,
etc.);
 on endocrine or ophthalmologic deficit.
.2.1.  NF  microincidentaloma
In asymptomatic enclosed intrasellar forms not in contact
ith the optic chiasm, surveillance as described above is a justi-
able attitude. Tumor regression, reported in 10–29% of cases,
rgues for such non-intervention [33,48]. Only progression indi-
ates surgery; no threshold size increase can be specified, as age,
omorbidity and proximity to the chiasm are also to be taken into
ccount: the decision is to be made on a case-by-case basis, in
iscussion with the patient [37].
.2.2. NF  macroincidentaloma
.2.2.1. NF  macroincidentaloma  with  normal  assessment
esults. In NF macroincidentaloma with normal assessment
esults, decision-making is based on the natural history of pitu-
tary adenoma, the postoperative reversibility of ophthalmic
nd/or endocrine symptoms, and the clinical context.
Given an aspect of adenoma on imaging, surveillance on the
bove schedule should be considered if there is a safety margin
ith respect to the chiasm (e.g., 2–3 mm), especially in elderly
atients and/or in case of comorbidity. Invasion of cavernous
pace is not a reason for active primary treatment, as surgery will drinologie 76 (2015) 191–200
ot cure the patient. If there is no contact with the visual path-
ay, there is no reason for ophthalmologic follow-up. Tumor
rogression (no specified threshold) indicates surgery.
In four particular cases, surgery is indicated as primary treat-
ent:
 desire for pregnancy in the short-term, given the risk of growth
of incidentalomas/adenomas during pregnancy (see guide-
lines in Castinetti et al., in the present consensus document);
 differential diagnostic doubt with respect to malignancy
(although malignant lesions are rarely asymptomatic);
 non-compliant patient liable to escape follow-up;
 and associated NF pituitary macroadenoma, male gender,
proximity to chiasm and anticoagulation therapy, as this
entails elevated risk of apoplexy, which can have serious con-
sequences [35]: first-line surgery can be discussed with the
patient, depending on the risk associated with interruption of
anticoagulation therapy.
If the distance from the chiasm is short or there is contact,
rst-line surgery should be discussed with the patient, based on:
 risk of progression and symptom onset reported in follow-
up studies (20–50% rates of increasing volume over 5 years)
[17,27,48];
 risk of apoplexy (depending on the report, 10% at 5 years [17]
or 1.6% to 12.8% [35] with risk of ophthalmologic disorder
and definitive endocrine deficiency [35]);
 better ophthalmologic and endocrine results reported in
asymptomatic patients [34,49].
The context may, however, make surveillance or absten-
ion preferable (elderly patient with comorbidities, or refusal
f surgery).
.2.2.2.  Symptomatic  NF  macroincidentaloma.  The Endocrine
ociety guidelines favor surgical management [37].
We also recommend discussing surgery in case of visual
isorder and/or anterior pituitary insufficiency.
The context may, however, make surveillance or absten-
ion preferable (elderly patient with comorbidities, or refusal
f surgery). Medical treatment (dopaminergic agonists,
omatostatin analogs) may be discussed (see guidelines in
ortet-Rudelli et al., in the present consensus document).
.  Decision-tree  for  the  management  of  pituitary
ncidentalomaThe decision-tree below (Fig. 1) encapsulates the recommen-
ations for the management of pituitary incidentaloma.
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